Mirum Pharmaceuticals Inc (MIRM)
$38.77
Live
Performance
- $38.31$39.39$38.77
1.19%
Downside
Day's Volatility :2.74%
Upside
1.57%
- $23.14$45.23$38.77
40.31%
Downside
52 Weeks Volatility :48.84%
Upside
14.28%
Returns
| Period | Mirum Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -0.18% | 3.6% | 0.0% |
6 Months | 63.26% | 10.2% | 0.0% |
1 Year | 41.48% | 19.6% | 0.0% |
3 Years | 150.54% | 16.8% | -23.0% |
Highlights
Market Capitalization | 1.9B |
Book Value | $4.81 |
Earnings Per Share (EPS) | -2.31 |
Wall Street Target Price | 61.3 |
Profit Margin | -41.29% |
Operating Margin TTM | -31.12% |
Return On Assets TTM | -12.27% |
Return On Equity TTM | -70.98% |
Revenue TTM | 264.4M |
Revenue Per Share TTM | 5.81 |
Quarterly Revenue Growth YOY | 107.69999999999999% |
Gross Profit TTM | 64.7M |
EBITDA | -88.8M |
Diluted Eps TTM | -2.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.77 |
EPS Estimate Next Year | -0.81 |
EPS Estimate Current Quarter | -0.47 |
EPS Estimate Next Quarter | -0.37 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 58.11%
Technicals Summary
Sell
Neutral
Buy
Mirum Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Mirum Pharmaceuticals Inc | 1.36% | 63.26% | 41.48% | 150.54% | 404.6% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Mirum Pharmaceuticals Inc | NA | NA | NA | -1.77 | -0.71 | -0.12 | NA | 4.81 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Mirum Pharmaceuticals Inc | Buy | $1.9B | 404.6% | NA | -41.29% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Mirum Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 69.22M → 77.87M (in $), with an average increase of 11.1% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -33.14M → -24.63M (in $), with an average increase of 16.9% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 46.4%
Institutional Holdings
HHG PLC
10.46%Bvf Inc
9.16%Eventide Asset Management, LLC
7.58%BlackRock Inc
6.79%Vanguard Group Inc
5.13%Rock Springs Capital Management LP
3.71%
Corporate Announcements
Mirum Pharmaceuticals Inc Earnings
Mirum Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Organization | Mirum Pharmaceuticals Inc |
Employees | 294 |
CEO | Mr. Christopher Peetz |
Industry | Health Technology |
Discover More
International Select Dividend Ishares
$38.77
-1.75%
Vanguard Ultra Short Bond Et
$38.77
-1.75%
Core Scientific Inc
$38.77
-1.75%
Integer Holdings Corp
$38.77
-1.75%
Liberty Global Plc - Class C Shares
$38.77
-1.75%
Pampa Energia Sa
$38.77
-1.75%
Icf International Inc
$38.77
-1.75%
Pacific Premier Bancorp Inc
$38.77
-1.75%
Macy's, Inc.
$38.77
-1.75%